Markets:

Overview

News

Currencies

International

Treasuries

Ionis Pharmaceuticals, Inc. - Common Stock (NQ:IONS)

83.91 +2.42 (+2.97%)

Streaming Delayed Price Updated: 1:24 PM EST, Jan 7, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Ionis Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Ionis reports first quarter 2025 financial results

April 30, 2025

From Ionis Pharmaceuticals, Inc.

Via Business Wire

Earnings Scheduled For April 30, 2025 ↗

April 30, 2025

Via Benzinga

New Harris Poll findings reveal HAE patients are unsatisfied with current prophylactic treatment options, with over 90% interested in trying new therapies

April 29, 2025

From Ionis Pharmaceuticals, Inc.

Via Business Wire

Ionis to hold first quarter 2025 financial results webcast

April 16, 2025

From Ionis Pharmaceuticals, Inc.

Via Business Wire

What Analysts Are Saying About Ionis Pharmaceuticals Stock ↗

March 11, 2025

Via Benzinga

What Analysts Are Saying About Ionis Pharmaceuticals Stock ↗

February 20, 2025

Via Benzinga

Earnings Scheduled For February 19, 2025 ↗

February 19, 2025

Via Benzinga

The Analyst Verdict: Ionis Pharmaceuticals In The Eyes Of 5 Experts ↗

January 15, 2025

Via Benzinga

Drugmaker Ionis Pharmaceuticals Garners Analyst Praise For 'Pipeline Depth' ↗

April 07, 2025

HC Wainwright initiates Ionis with Buy rating and $45 target, citing strong pipeline, solid revenue, and key clinical milestones ahead.

Via Benzinga

This Reddit Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗

April 07, 2025

Via Benzinga

Ionis to host expert panel discussion on sHTG

April 03, 2025

From Ionis Pharmaceuticals, Inc.

Via Business Wire

Assessing Ionis Pharmaceuticals: Insights From 8 Financial Analysts ↗

March 31, 2025

Via Benzinga

The Analyst Verdict: Ionis Pharmaceuticals In The Eyes Of 6 Experts ↗

December 20, 2024

Via Benzinga

Ionis to present at upcoming investor conferences

March 31, 2025

From Ionis Pharmaceuticals, Inc.

Via Business Wire

Competitive Analysis In The ATTR-CM Field ↗

March 30, 2025

Precision medicine was proved in the ATTR-CM field. We think acoramidis is a more potent TTR stabilizer and that it will attract first-line patients. Tafamidis, acoramidis and vutrisiran will share the...

Via Talk Markets

Topics Stocks / Equities

Ionis expands partnership with Sobi to include olezarsen commercialization outside the U.S.

March 26, 2025

From Ionis Pharmaceuticals, Inc.

Via Business Wire

Ionis Pharmaceuticals Partners With Japan-Based Ono Pharmaceutical For Rare Blood Disease Drug In Over $800 Million Deal ↗

March 12, 2025

Ionis grants Ono global rights to sapablursen for polycythemia vera in a deal worth up to $940M, including milestones and royalties on future sales.

Via Benzinga

Ionis and Ono announce global license agreement for sapablursen in polycythemia vera

March 11, 2025

From Ionis Pharmaceuticals, Inc.

Via Business Wire

WAINZUA (eplontersen) approved in the EU for the treatment of hereditary transthyretin-mediated amyloidosis in adults with stage 1 or stage 2 polyneuropathy

March 10, 2025

From Ionis Pharmaceuticals, Inc.

Via Business Wire

Ionis to present at upcoming investor conferences

February 25, 2025

From Ionis Pharmaceuticals, Inc.

Via Business Wire

New positive donidalorsen data to be presented at AAAAI/WAO Joint Congress highlight sustained HAE attack rate reduction and disease control

February 20, 2025

From Ionis Pharmaceuticals, Inc.

Via Business Wire

Ionis Pharma Beats Expectations for Q4 ↗

February 19, 2025

The biotech outperformed expectations with better-than-expected revenue and a smaller-than-expected loss.

Via The Motley Fool

Ionis Pharmaceuticals Q4 Revenue Growth Exceeds Guidance, Forecasts Over $600 Million In 2025 Sales ↗

February 19, 2025

Ionis Pharmaceuticals posted a smaller-than-expected Q4 loss and exceeded revenue estimates. The company projects 2025 revenue of over $600 million.

Via Benzinga

Ionis reports fourth quarter and full year 2024 financial results

February 19, 2025

From Ionis Pharmaceuticals, Inc.

Via Business Wire

Ionis to hold fourth quarter and full year 2024 financial results webcast

February 05, 2025

From Ionis Pharmaceuticals, Inc.

Via Business Wire

FDA and EMA Accept Applications for Higher Dose Regimen of Nusinersen in SMA

January 23, 2025

Applications are based on data from the DEVOTE study, which demonstrate the potential for the investigational higher dose regimen of nusinersen to advance the treatment of SMA

From Biogen Inc.

Via GlobeNewswire

Denali Therapeutics' Amyotrophic Lateral Sclerosis Misses Pivotal Trial, But Analyst Says It Was Expected ↗

January 07, 2025

Denali's DNL343 missed efficacy goals in the HEALEY ALS trial but was well-tolerated. Analysts await detailed biomarker data and subgroup analyses in 2025.

Via Benzinga

Denali Therapeutics Ratchets Up Losses On Misstep In ALS Treatment. Why The Game Isn't Over Yet. ↗

January 07, 2025

One analyst says the six-month study was too short and the benefits could appear over time.

Via Investor's Business Daily

Denali Therapeutics Neurodegenerative Disease Platform Sparks Analyst Optimistic ↗

January 03, 2025

William Blair starts coverage on Denali Therapeutics with an Outperform rating, citing its transport vehicle platform and promising therapies for neurodegenerative diseases.

Via Benzinga

FDA Approves Ionis Pharmaceuticals' Rare Genetic Disease Therapy to Lower High-Level Of Fat In Blood ↗

December 20, 2024

Ionis' Tryngolza receives FDA approval for familial chylomicronemia syndrome, showing significant triglyceride reduction and fewer pancreatitis events.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.